NCT01052467 is a clinical trial of Xamiol® Gel in Scalp Psoriasis, sponsored by LEO Pharma.

Who is sponsoring NCT01052467?

NCT01052467 is sponsored by LEO Pharma.

What drugs are being tested in NCT01052467?

Interventions in NCT01052467: Xamiol® Gel.

What condition does NCT01052467 study?

NCT01052467 studies Scalp Psoriasis.

Is NCT01052467 still recruiting?

NCT01052467 is currently completed. Last updated 21 February 2025.

Last reviewed 2025-02-21 · How we verify

NCT01052467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Completed Last updated 21 February 2025

What this trial tests

trial testing Xamiol® Gel in Scalp Psoriasis in 724 participants. Completed in 1 May 2010.

Timeline

1 January 2010

Primary endpoint
1 May 2010

1 May 2010

Quick facts

Lead sponsor	LEO Pharma
Status	Completed
Study type	OBSERVATIONAL
Enrollment	724
Start date	1 January 2010
Primary completion	1 May 2010
Estimated completion	1 May 2010
Sites	1 location across Germany

Drugs / interventions tested

Xamiol® Gel — full drug profile →

Conditions studied

Scalp Psoriasis — all drugs for Scalp Psoriasis →

Sponsor

LEO Pharma — full company profile →

Who can join

18 and older, any sex, with Scalp Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Physician's Global Assessment of scalp psoriasis
Time frame: After approximately 4 weeks

Sponsor's own description

This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in quality-of-life parameters in patients with scalp psoriasis

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other LEO Pharma trials

Trials by the same sponsor.

NCT07335588 — A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus · Phase 3 · not yet recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to · Phase 2 · recruiting
NCT06444867 — A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 15896 · Phase 1 · completed
NCT06311682 — A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and · Phase 3 · recruiting
NCT05923099 — A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic De · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01052467 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LEO Pharma
Last refreshed: 21 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01052467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing